Few sectors have been impacted by healthcare reform more than the orthopedics industry. And the looming merger of Zimmer and Biomet threatens to bring even more change and further consolidation. To get another perspective, FierceMedicalDevices spoke with Todd Ebert, the CEO of group purchasing organization Amerinet.
FierceMedicalDevices is putting together a list of the "Top 10 Women in Med Tech" for the very first time this year to honor top innovators, dealmakers and other standouts in the sector. And we have opened our online form for nominating women for this year's feature. Submit your nominations here.
While medical device venture activity may have picked up this year, the comparison point in 2013 was abysmally low. In addition, Series A device investment was still shrinking. That's according to a new report from Silicon Valley Bank. These trends are pushing the sector to be more reliant on angel investors, which are becoming more accessible with the advent of crowdfunding, and corporate VCs, who are stealthy but increasingly active.
I caught up with Dr. Tom Frieden, director of the U.S. Centers for Disease Control and Prevention, last week, prior to his address at the National Press Club in downtown Washington, DC. Other media outlets joined in later. Here are some takeaways from his speech on antibiotic resistance, as well as our conversation.
Last year's Fierce 15 med tech winners include an implant maker for sinusitus that recently filed for an $80 million IPO, a fierce competitor to device giants Medtronic and Edwards Lifesciences in the emerging market for minimally invasive heart valves and a market leader in developing nerve-stimulating implant for rheumatoid arthritis and Crohn's disease. What will 2014 bring? That depends on you.
A slump in FDA premarket approvals in 2013 set a somber tone for the coming year. As EP Vantage reported in its "MedTech 2013 in Review," the agency's PMA approval rates were down 44% in 2013 from 2012, with only 23 approvals compared to 41 the previous year. Medical device makers are still struggling to bring their products to market, but a few companies celebrated big regulatory wins in 2014.
On a cold January morning in 2013, my big sister, Gretchen, took her last, labored breath and died. She was 46. Over the course of her last month alive, I developed a growing sense of anger and desperation at how her doctors, as well as the drug and diagnostics industries, seemed to have failed her.
In 2013, a number of outside forces hammered the med tech industry. While things could have been better, most of the top 10 companies in the sector still enjoyed moderate year-over-year revenue gains.
On Jan. 2, 2014, a pacemaker was implanted under my right clavicle, with two wire leads snaked through two veins and into my heart. My experience as a patient showed me how limited the true choices are for most U.S. cardiac patients, despite the marketing hype around innovation in the industry.
Christopher Jones flew in from the U.K. to San Francisco on Jan. 10 to get a head start on celebrating milestones and networking. But the 2014 JPMorgan Healthcare Conference, which began on Jan. 13, was high on his agenda.